Library · Metabolic & weight · Treatment of severe hypoglycemia in diabetes patients
Dasiglucagon
ZP4207, Zealand peptide analog of glucagon
Stable, soluble glucagon analog approved (Zegalogue) for severe hypoglycemia in adults and children with diabetes. Comes as a ready-to-use liquid, unlike traditional glucagon that needs reconstituting.
Research score 85/100. Reference only, not a dose.
- Blood Sugar Control
- Metabolic Enhancement
- Hormone Regulation
- GLP-1 Agonist
- US status
- Prescription Only
- Approval
- FDA Approved
- Evidence
- FDA Approved (Zegalogue) for severe hypoglycemia.
- Research score
- 85 / 100
- Indication
- Hypoglycemia
- Origin
- Denmark
- Source category
- Digestive System
- Status group
- Approved / prescription
Mechanism
Agonizes the glucagon receptor on liver cells, raising cAMP to activate glycogen phosphorylase and inhibit glycogen synthase, releasing stored glucose, while also boosting gluconeogenesis enzymes like PEPCK.
Safety file
Nausea, vomiting, and headache are common; generally considered safe for emergency rescue use.
- Nausea
- Vomiting
- Headache
- Diarrhea
- Injection site reactions